Reindl T, Degenhardt P, Luck W, Riebel T, Sarioglu N, Henze G, Driever P Hernáiz
Klinik für Pädiatrie m. S. Onkologie/Hämatologie. Otto Heubner Zentrum für Kinder und Jugendmedizin.
Klin Padiatr. 2004 Sep-Oct;216(5):264-9. doi: 10.1055/s-2004-44901.
Vasoactive intestinal peptide (VIP) can be produced by mature neurogenic tumors. Pathologically elevated VIP plasma levels cause secretory diarrhea with excessive loss of water and electrolytes. Despite the clinical severity diagnosis of a VIP-secreting tumor is often delayed and subsequently its extirpation as the mainstay of therapy.
We report on two patients with ganglioneuroblastoma and secretory diarrhea. We contrast the case of a 13-month-old boy with advanced symptoms of secretory diarrhea, high VIP plasma levels, and late diagnosis to the case of a 14-month-old boy with mild secretory diarrhea and normal VIP plasma levels but positive proof of VIP in tumor tissue. Reviewing the literature we found 57 cases of pediatric VIP-secreting tumors.
The clinical situation is characterized by the typical symptoms of secretory diarrhea with hypokalemia and metabolic acidosis. Histopathology predominantly reveals ganglioneuroblastoma or ganglioneuroma. The symptoms mostly stop after complete resection of the tumor whereas lack of resection is associated with elevated mortality rates.
In case of prolonged therapy-resistant secretory diarrhea the existence of a VIP-secreting tumor should be considered. Diagnostic work-up should include the assessment of VIP plasma levels, catecholamines in urine, and appropriate imaging techniques in order to rule out or confirm the possibility of a VIP producing tumor.
血管活性肠肽(VIP)可由成熟的神经源性肿瘤产生。病理情况下,血浆VIP水平升高会导致分泌性腹泻,伴有水和电解质的过度流失。尽管临床症状严重,但分泌性腹泻型肿瘤的诊断往往延迟,随后其切除成为主要治疗手段。
我们报告了两例患有神经节神经母细胞瘤和分泌性腹泻的患者。我们将一名13个月大、有分泌性腹泻晚期症状、血浆VIP水平高且诊断较晚的男孩的病例,与一名14个月大、有轻度分泌性腹泻、血浆VIP水平正常但肿瘤组织中VIP检测呈阳性的男孩的病例进行对比。查阅文献后,我们发现了57例儿童分泌性腹泻型肿瘤病例。
临床情况以分泌性腹泻伴低钾血症和代谢性酸中毒的典型症状为特征。组织病理学主要显示为神经节神经母细胞瘤或神经节神经瘤。肿瘤完全切除后症状大多会消失,而未切除则与死亡率升高有关。
对于长期治疗抵抗的分泌性腹泻,应考虑存在分泌性腹泻型肿瘤。诊断检查应包括评估血浆VIP水平、尿中儿茶酚胺以及适当的成像技术,以排除或确认分泌性腹泻型肿瘤的可能性。